Abstract
In The Lancet HIV, Adrie Bekker and colleagues1 report the first evidence-based optimal dosing guidance for infants younger than 3 months receiving abacavir liquid formulation. The authors applied a population pharmacokinetic modelling approach to pool data from three different studies and predict abacavir exposure in infants over time.1 This method allowed for simulation of various dosing scenarios without exposing infants to experimental abacavir dosages. The dose recommendations have already been included in the 2021 WHO paediatric treatment guideline.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
